100981-43-9
Chemical Structure
Ebrotidine
Synonym(s): FI3542
- CAS No.: 100981-43-9
- Formula:C14H17BrN6O2S3
- Molecular Weight:477.42
IUPAC Name: (E)-N'-((4-bromophenyl)sulfonyl)-N-(2-(((2-guanidinothiazol-4-yl)methyl)thio)ethyl)formimidamide
InChIKey: ZQHFZHPUZXNPMF-UHFFFAOYSA-N
SMILES: O=S(C1=CC=C(Br)C=C1)(/N=C/NCCSCC2=CSC(NC(N)=N)=N2)=O
Biological Activity: Ebrotidine (FI3542) is a competitive histamine H2 receptor (histamine H2 receptor) antagonist with gastric acid secretion inhibitory and gastric mucosal protective effects. Ebrotidine alleviates gastric mucosal injury and epithelial cell apoptosis induced by Indomethacin (HY-14397) and Helicobacter pylori LPS (HY-D1056), and accelerates chronic gastric ulcer healing by promoting rapid recovery of IL-4 and inhibiting TNF-α, endothelin-1 (ET-1) and NOS-2. Ebrotidine can be used in studies on gastric ulcer healing, NSAID-induced gastric mucosal injury, Helicobacter pylori-associated gastritis, and H2 receptor-mediated gastric mucosal protection mechanisms[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ebrotidine | 98.08% | Ebrotidine (FI3542) is a competitive histamine H2 receptor (histamine H2 receptor) antagonist with gastric acid secretion inhibitory and gastric mucosal protective effects. Ebrotidine alleviates gastric mucosal injury and epithelial cell apoptosis induced by Indomethacin (HY-14397) and Helicobacter pylori LPS (HY-D1056), and accelerates chronic gastric ulcer healing by promoting rapid recovery of IL-4 and inhibiting TNF-α, endothelin-1 (ET-1) and NOS-2. Ebrotidine can be used in studies on gastric ulcer healing, NSAID-induced gastric mucosal injury, Helicobacter pylori-associated gastritis, and H2 receptor-mediated gastric mucosal protection mechanisms. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ebrotidine (Standard) | ≥98% | Ebrotidine (Standard) (FI3542 (Standard)) is the analytical standard of Ebrotidine (HY-15538). This product is intended for research and analytical applications. Ebrotidine (FI3542) is a competitive histamine H2 receptor (histamine H2 receptor) antagonist with gastric acid secretion inhibitory and gastric mucosal protective effects. Ebrotidine alleviates gastric mucosal injury and epithelial cell apoptosis induced by Indomethacin (HY-14397) and Helicobacter pylori LPS (HY-D1056), and accelerates chronic gastric ulcer healing by promoting rapid recovery of IL-4 and inhibiting TNF-α, endothelin-1 (ET-1) and NOS-2. Ebrotidine can be used in studies on gastric ulcer healing, NSAID-induced gastric mucosal injury, Helicobacter pylori-associated gastritis, and H2 receptor-mediated gastric mucosal protection mechanisms. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Romero A, et al. Study of the Population of Enterochromaffin-Like Cells in Mouse Gastric Mucosa after Long-Term Treatment with Ebrotidine. Toxicologic Pathology. 1996;24(2):160-165.
- [2]. Romero A, et al. Effect of ebrotidine on the density of antral G-cells in the gastric mucosa in the rat. Cell proliferation. 1995 Jul;28(7):393-401.
- [3]. Slomiany BL, et al. Involvement of interleukin-4 in down-regulation of endothelin-1 during gastric ulcer healing: Effect of ebrotidine. Inflammopharmacology. 2000;8(1):55-68.
- [4]. Slomiany BL, et al. Induction of tumor necrosis factor-alpha and apoptosis in gastric mucosal injury by indomethacin: effect of omeprazole and ebrotidine. Scandinavian journal of gastroenterology. 1997 Jul;32(7):638-42.
- [5]. Romero A, et al. Twenty-four-month oral carcinogenicity study of ebrotidine in rats. Teratogenesis, carcinogenesis, and mutagenesis. 1998;18(6):263-77.
- [6]. Slomiany BL, et al. Effect of ebrotidine on Helicobacter pylori lipopolysaccharide-induced up-regulation of endothelin-1 in gastric mucosa. Journal of Endotoxin Research. 1999;5(5/6):279-285.
